Summary Basis of Decision for Eydenzelt
Health Canada issued a Notice of Compliance for Eydenzelt (sapanisertib) for the treatment of patients with advanced renal cell carcinoma who have received…
Impact analysis · 53/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
Health Canada issued a Notice of Compliance for Eydenzelt (sapanisertib) for the treatment of patients with advanced renal cell carcinoma who have received prior systemic therapy. This decision is final and based on review of submitted clinical data.
Quantitative evidence
- Approved indication: advanced renal cell carcinoma
- Active substance: sapanisertib
- Application type: New Drug Submission
- Population: post-systemic therapy patients
- Pivotal trial name/number
- Exact n= for approval
- Efficacy results
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
Eydenzelt is a kinase inhibitor targeting mTOR. Approval is for advanced renal cell carcinoma patients previously treated with systemic therapy.
Market context
As a therapy for advanced kidney cancer, Eydenzelt may compete with established products in the post-systemic treatment setting.
Legal and regulatory context
The Notice of Compliance is a final regulatory approval authorizing Eydenzelt for sale in Canada.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- 4f8acc27734b846952a05c2a319783accd6403275554c073e188eac766e8cffe
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-06-05T213025Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.